Mould exposure significantly increased chance of COPD flare up in study miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Public invited to #BePartOfResearch as Greater Manchester reveals its research response to the COVID-19 pandemic Date published: 20 May 2021
The National Institute for Health Research (NIHR) in Greater Manchester is hosting the webinar, which takes place from 1pm tomorrow (Friday)
People are invited to an online event to hear how Greater Manchester has played a key part in the groundbreaking research which has turned the tide on COVID-19.
The National Institute for Health Research (NIHR) in Greater Manchester is hosting the webinar, which takes place from 1pm tomorrow (Friday).
Anyone can attend.
It follows-on from International Clinical Trials Day today and is the start of NIHR’s month-long #BePartOfResearch public awareness campaign.
, England’s largest NHS trust, has recruited its final participant to a leading COVID-19 vaccine trial.
The Phase 3 study is testing the safety and effectiveness of a new two-dose vaccine regimen, versus a placebo, in preventing moderate to severe/critical coronavirus disease.
The vaccine candidate has been developed by The Janssen Pharmaceutical Companies of Johnson & Johnson, as researchers around the world continue to work to secure a range of vaccines and treatments to help tackle coronavirus.
Dr Tim Felton, an Honorary Consultant at MFT’s Wythenshawe Hospital, is the Trust’s Clinical Lead for all COVID-19 research, as well as the Principal Investigator at MFT for the Janssen Phase 3 study.
The NIHR-supported Novavax COVID-19 vaccine is 89.3% effective at preventing COVID-19.
This is according to the interim analysis of Phase III study data, including effectiveness against the new variants of concern.
More than 1,240 Greater Manchester volunteers are taking part in the study, including almost 500 from Oldham.
The Novavax study is the largest ever double blind, placebo-controlled trial to be undertaken in the UK.
It recruited over 15,000 participants from 35 research UK sites in just over two months.
It was the first phase 3 study for the US-based biotechnology firm Novavax’s vaccine anywhere in the world.
In Greater Manchester, the study has been carried out by local research teams at two community sites.